Axsome Therapeutics (AXSM) Other Accumulated Expenses (2015 - 2026)

Axsome Therapeutics has reported Other Accumulated Expenses for 11 years, with the latest figure at $12.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 54.88% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (up 54.88% YoY) and the FY2025 annual result came in at $7.9 million, down 20.65% from the prior year.
• Other Accumulated Expenses improved to $12.2 million in Q1 2026 per AXSM's latest filing, from $7.9 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $12.2 million in Q1 2026 and troughed at $705583.0 in Q2 2022.
• A 5-year average of $6.1 million and a median of $6.3 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses jumped 1052.1% in 2023, then sank 50.94% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $1.6 million in 2022, then jumped by 266.54% to $5.9 million in 2023, then soared by 68.01% to $10.0 million in 2024, then declined by 20.65% to $7.9 million in 2025, then soared by 55.0% to $12.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $12.2 million, $7.9 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.